Cargando…
Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoret...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927574/ https://www.ncbi.nlm.nih.gov/pubmed/33675992 http://dx.doi.org/10.1016/j.tracli.2021.02.005 |
_version_ | 1783659699315408896 |
---|---|
author | Focosi, D. Franchini, M. |
author_facet | Focosi, D. Franchini, M. |
author_sort | Focosi, D. |
collection | PubMed |
description | Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs. |
format | Online Article Text |
id | pubmed-7927574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79275742021-03-04 Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency Focosi, D. Franchini, M. Transfus Clin Biol Editorial Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs. Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021-05 2021-03-03 /pmc/articles/PMC7927574/ /pubmed/33675992 http://dx.doi.org/10.1016/j.tracli.2021.02.005 Text en © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Editorial Focosi, D. Franchini, M. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency |
title | Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency |
title_full | Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency |
title_fullStr | Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency |
title_full_unstemmed | Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency |
title_short | Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency |
title_sort | impact of pathogen-reduction technologies on covid-19 convalescent plasma potency |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927574/ https://www.ncbi.nlm.nih.gov/pubmed/33675992 http://dx.doi.org/10.1016/j.tracli.2021.02.005 |
work_keys_str_mv | AT focosid impactofpathogenreductiontechnologiesoncovid19convalescentplasmapotency AT franchinim impactofpathogenreductiontechnologiesoncovid19convalescentplasmapotency |